Onko MD Special GU ASCO 2026 brings a selection of the most important data from the field of oncology, specifically focused on urogenital tumors. The newsletter focuses on news that may gradually affect clinical practice. Issue #14 has a special focus on data from GU ASCO 2026. One of the studies presented is PEACE-3, which investigated the combination of enzalutamide and radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. The study showed an improvement in overall survival (OS) with combined treatment, but at the cost of higher toxicity. The question remains what the real benefit of this combination will be in current clinical practice, considering the pretreatment of patients with abiraterone.